Bioactive glass S53P4 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bioactive glass S53P4" in English language version.

refsWebsite

Global rank English rank

17doi.org

2^nd place

17nih.gov

4^th place

10semanticscholar.org

11^th place

8^th place

2bonalive.com

low place

1sorbonne-universite.fr

low place

1handle.net

102^nd place

76^th place

1fliphtml5.com

low place

bonalive.com

"Our story, Glass into bone". Bonalive Biomaterials. Bonalive Biomaterials Ltd. Retrieved May 11, 2020.
"Bacterial growth inhibition of Bonalive® granules", version 91310f/1" (PDF). Bonalive Biomaterials Ltd. Retrieved June 12, 2020.

doi.org

Cunha MT, Murça MA, Nigro S, Klautau GB, Salles MJ (April 2018). "In vitro antibacterial activity of bioactive glass S53P4 on multiresistant pathogens causing osteomyelitis and prosthetic joint infection". BMC Infectious Diseases. 18 (1). BioMed Central: 157. doi:10.1186/s12879-018-3069-x. PMC 5883601. PMID 29614973.
Virolainen P, Heikkilä J, Yli-Urpo A, Vuorio E, Aro HT (April 1997). "Histomorphometric and molecular biologic comparison of bioactive glass granules and autogenous bone grafts in augmentation of bone defect healing". Journal of Biomedical Materials Research. 35 (1): 9–17. doi:10.1002/(SICI)1097-4636(199704)35:1<9::AID-JBM2>3.0.CO;2-S. PMID 9104694.
Zhang D, Leppäranta O, Munukka E, Ylänen H, Viljanen MK, Eerola E, et al. (May 2010). "Antibacterial effects and dissolution behavior of six bioactive glasses". Journal of Biomedical Materials Research. Part A. 93 (2): 475–83. doi:10.1002/jbm.a.32564. PMID 19582832.
Leppäranta O, Vaahtio M, Peltola T, Zhang D, Hupa L, Hupa M, et al. (February 2008). "Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro". Journal of Materials Science: Materials in Medicine. 19 (2): 547–51. doi:10.1007/s10856-007-3018-5. PMID 17619981. S2CID 21444777.
Drago L, De Vecchi E, Bortolin M, Toscano M, Mattina R, Romanò CL (2015). "Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains". Future Microbiology. 10 (8): 1293–9. doi:10.2217/FMB.15.57. PMID 26228640.
Drago L, Vassena C, Fenu S, De Vecchi E, Signori V, De Francesco R, Romanò CL (2014). "In vitro antibiofilm activity of bioactive glass S53P4". Future Microbiology. 9 (5): 593–601. doi:10.2217/fmb.14.20. PMID 24957087.
de Veij Mestdagh PD, Colnot DR, Borggreven PA, Orelio CC, Quak JJ (July 2017). "Mastoid obliteration with S53P4 bioactive glass in cholesteatoma surgery". Acta Oto-Laryngologica. 137 (7): 690–694. doi:10.1080/00016489.2017.1279346. PMID 28125327. S2CID 4520396.
Bernardeschi D, Pyatigorskaya N, Russo FY, De Seta D, Corallo G, Ferrary E, et al. (April 2017). "Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass s53p4: a prospective clinical study" (PDF). Clinical Otolaryngology. 42 (2): 387–396. doi:10.1111/coa.12748. PMID 27608143. S2CID 1060470.
Vos J, de Vey Mestdagh P, Colnot D, Borggreven P, Orelio C, Quak J (December 2017). "Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients". European Archives of Oto-Rhino-Laryngology. 274 (12): 4121–4126. doi:10.1007/s00405-017-4757-7. PMID 28956143. S2CID 20851852.
Bigoni M, Turati M, Zanchi N, Lombardo AS, Graci J, Omeljaniuk RJ, et al. (April 2019). "Clinical applications of Bioactive glass S53P4 in bone infections: a systematic review". European Review for Medical and Pharmacological Sciences. 23 (2 Suppl): 240–251. doi:10.26355/eurrev_201904_17498. PMID 30977891. S2CID 109940029.
Godoy-Santos AL, Rosemberg LA, de Cesar-Netto C, Armstrong DG (January 2019). "The use of bioactive glass S53P4 in the treatment of an infected Charcot foot: a case report". Journal of Wound Care. 28 (Sup1): S14 – S17. doi:10.12968/jowc.2019.28.Sup1.S14. PMID 30724119. S2CID 73428010.
Malat TA, Glombitza M, Dahmen J, Hax PM, Steinhausen E (April 2018). "The Use of Bioactive Glass S53P4 as Bone Graft Substitute in the Treatment of Chronic Osteomyelitis and Infected Non-Unions – a Retrospective Study of 50 Patients". Zeitschrift für Orthopädie und Unfallchirurgie. 156 (2): 152–159. doi:10.1055/s-0043-124377. PMID 29665602. S2CID 263428196.
Lindfors N, Geurts J, Drago L, Arts JJ, Juutilainen V, Hyvönen P, et al. (2017). "Antibacterial Bioactive Glass, S53P4, for Chronic Bone Infections – A Multinational Study". A Modern Approach to Biofilm-Related Orthopaedic Implant Infections. Advances in Experimental Medicine and Biology. Vol. 971. pp. 81–92. doi:10.1007/5584_2016_156. hdl:10138/252437. ISBN 978-3-319-52273-9. PMID 28050878. S2CID 22072415.
Frantzén J, Rantakokko J, Aro HT, Heinänen J, Kajander S, Gullichsen E, et al. (October 2011). "Instrumented spondylodesis in degenerative spondylolisthesis with bioactive glass and autologous bone: a prospective 11-year follow-up". Journal of Spinal Disorders & Techniques. 24 (7): 455–61. doi:10.1097/BSD.0b013e31822a20c6. PMID 21909036. S2CID 28088570.
Rantakokko J, Frantzén JP, Heinänen J, Kajander S, Kotilainen E, Gullichsen E, Lindfors NC (2012). "Posterolateral spondylodesis using bioactive glass S53P4 and autogenous bone in instrumented unstable lumbar spine burst fractures. A prospective 10-year follow-up study". Scandinavian Journal of Surgery. 101 (1): 66–71. doi:10.1177/145749691210100113. PMID 22414472. S2CID 38296163.
Saarenpää I, Hirvonen J, Rinne J, Frantzén J (2018). "Novel bioactive glass putty (S53P4) as bone graft expander in minimally invasive lumbosacral interbody fusion". J Minim Invasive Spine Surg Tech. 3 (2): 52–8. doi:10.21182/jmisst.2018.00332.
Lindfors NC, et al. (2010). "A prospective randomized 14-year follow- up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumours". J Biomed Mater Res. 94B (1): 57–64. doi:10.1002/jbm.b.31636. PMID 20524190.

fliphtml5.com

Bonalive Smart Healing (EN), version 91308d/3. Bonalive Biomaterials Ltd. Retrieved May 11, 2020.

handle.net

hdl.handle.net

Lindfors N, Geurts J, Drago L, Arts JJ, Juutilainen V, Hyvönen P, et al. (2017). "Antibacterial Bioactive Glass, S53P4, for Chronic Bone Infections – A Multinational Study". A Modern Approach to Biofilm-Related Orthopaedic Implant Infections. Advances in Experimental Medicine and Biology. Vol. 971. pp. 81–92. doi:10.1007/5584_2016_156. hdl:10138/252437. ISBN 978-3-319-52273-9. PMID 28050878. S2CID 22072415.

nih.gov

pubmed.ncbi.nlm.nih.gov

Cunha MT, Murça MA, Nigro S, Klautau GB, Salles MJ (April 2018). "In vitro antibacterial activity of bioactive glass S53P4 on multiresistant pathogens causing osteomyelitis and prosthetic joint infection". BMC Infectious Diseases. 18 (1). BioMed Central: 157. doi:10.1186/s12879-018-3069-x. PMC 5883601. PMID 29614973.
Virolainen P, Heikkilä J, Yli-Urpo A, Vuorio E, Aro HT (April 1997). "Histomorphometric and molecular biologic comparison of bioactive glass granules and autogenous bone grafts in augmentation of bone defect healing". Journal of Biomedical Materials Research. 35 (1): 9–17. doi:10.1002/(SICI)1097-4636(199704)35:1<9::AID-JBM2>3.0.CO;2-S. PMID 9104694.
Zhang D, Leppäranta O, Munukka E, Ylänen H, Viljanen MK, Eerola E, et al. (May 2010). "Antibacterial effects and dissolution behavior of six bioactive glasses". Journal of Biomedical Materials Research. Part A. 93 (2): 475–83. doi:10.1002/jbm.a.32564. PMID 19582832.
Leppäranta O, Vaahtio M, Peltola T, Zhang D, Hupa L, Hupa M, et al. (February 2008). "Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro". Journal of Materials Science: Materials in Medicine. 19 (2): 547–51. doi:10.1007/s10856-007-3018-5. PMID 17619981. S2CID 21444777.
Drago L, De Vecchi E, Bortolin M, Toscano M, Mattina R, Romanò CL (2015). "Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains". Future Microbiology. 10 (8): 1293–9. doi:10.2217/FMB.15.57. PMID 26228640.
Drago L, Vassena C, Fenu S, De Vecchi E, Signori V, De Francesco R, Romanò CL (2014). "In vitro antibiofilm activity of bioactive glass S53P4". Future Microbiology. 9 (5): 593–601. doi:10.2217/fmb.14.20. PMID 24957087.
de Veij Mestdagh PD, Colnot DR, Borggreven PA, Orelio CC, Quak JJ (July 2017). "Mastoid obliteration with S53P4 bioactive glass in cholesteatoma surgery". Acta Oto-Laryngologica. 137 (7): 690–694. doi:10.1080/00016489.2017.1279346. PMID 28125327. S2CID 4520396.
Bernardeschi D, Pyatigorskaya N, Russo FY, De Seta D, Corallo G, Ferrary E, et al. (April 2017). "Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass s53p4: a prospective clinical study" (PDF). Clinical Otolaryngology. 42 (2): 387–396. doi:10.1111/coa.12748. PMID 27608143. S2CID 1060470.
Vos J, de Vey Mestdagh P, Colnot D, Borggreven P, Orelio C, Quak J (December 2017). "Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients". European Archives of Oto-Rhino-Laryngology. 274 (12): 4121–4126. doi:10.1007/s00405-017-4757-7. PMID 28956143. S2CID 20851852.
Bigoni M, Turati M, Zanchi N, Lombardo AS, Graci J, Omeljaniuk RJ, et al. (April 2019). "Clinical applications of Bioactive glass S53P4 in bone infections: a systematic review". European Review for Medical and Pharmacological Sciences. 23 (2 Suppl): 240–251. doi:10.26355/eurrev_201904_17498. PMID 30977891. S2CID 109940029.
Godoy-Santos AL, Rosemberg LA, de Cesar-Netto C, Armstrong DG (January 2019). "The use of bioactive glass S53P4 in the treatment of an infected Charcot foot: a case report". Journal of Wound Care. 28 (Sup1): S14 – S17. doi:10.12968/jowc.2019.28.Sup1.S14. PMID 30724119. S2CID 73428010.
Malat TA, Glombitza M, Dahmen J, Hax PM, Steinhausen E (April 2018). "The Use of Bioactive Glass S53P4 as Bone Graft Substitute in the Treatment of Chronic Osteomyelitis and Infected Non-Unions – a Retrospective Study of 50 Patients". Zeitschrift für Orthopädie und Unfallchirurgie. 156 (2): 152–159. doi:10.1055/s-0043-124377. PMID 29665602. S2CID 263428196.
Lindfors N, Geurts J, Drago L, Arts JJ, Juutilainen V, Hyvönen P, et al. (2017). "Antibacterial Bioactive Glass, S53P4, for Chronic Bone Infections – A Multinational Study". A Modern Approach to Biofilm-Related Orthopaedic Implant Infections. Advances in Experimental Medicine and Biology. Vol. 971. pp. 81–92. doi:10.1007/5584_2016_156. hdl:10138/252437. ISBN 978-3-319-52273-9. PMID 28050878. S2CID 22072415.
Frantzén J, Rantakokko J, Aro HT, Heinänen J, Kajander S, Gullichsen E, et al. (October 2011). "Instrumented spondylodesis in degenerative spondylolisthesis with bioactive glass and autologous bone: a prospective 11-year follow-up". Journal of Spinal Disorders & Techniques. 24 (7): 455–61. doi:10.1097/BSD.0b013e31822a20c6. PMID 21909036. S2CID 28088570.
Rantakokko J, Frantzén JP, Heinänen J, Kajander S, Kotilainen E, Gullichsen E, Lindfors NC (2012). "Posterolateral spondylodesis using bioactive glass S53P4 and autogenous bone in instrumented unstable lumbar spine burst fractures. A prospective 10-year follow-up study". Scandinavian Journal of Surgery. 101 (1): 66–71. doi:10.1177/145749691210100113. PMID 22414472. S2CID 38296163.
Lindfors NC, et al. (2010). "A prospective randomized 14-year follow- up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumours". J Biomed Mater Res. 94B (1): 57–64. doi:10.1002/jbm.b.31636. PMID 20524190.

ncbi.nlm.nih.gov

Cunha MT, Murça MA, Nigro S, Klautau GB, Salles MJ (April 2018). "In vitro antibacterial activity of bioactive glass S53P4 on multiresistant pathogens causing osteomyelitis and prosthetic joint infection". BMC Infectious Diseases. 18 (1). BioMed Central: 157. doi:10.1186/s12879-018-3069-x. PMC 5883601. PMID 29614973.

semanticscholar.org

api.semanticscholar.org

Leppäranta O, Vaahtio M, Peltola T, Zhang D, Hupa L, Hupa M, et al. (February 2008). "Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro". Journal of Materials Science: Materials in Medicine. 19 (2): 547–51. doi:10.1007/s10856-007-3018-5. PMID 17619981. S2CID 21444777.
de Veij Mestdagh PD, Colnot DR, Borggreven PA, Orelio CC, Quak JJ (July 2017). "Mastoid obliteration with S53P4 bioactive glass in cholesteatoma surgery". Acta Oto-Laryngologica. 137 (7): 690–694. doi:10.1080/00016489.2017.1279346. PMID 28125327. S2CID 4520396.
Bernardeschi D, Pyatigorskaya N, Russo FY, De Seta D, Corallo G, Ferrary E, et al. (April 2017). "Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass s53p4: a prospective clinical study" (PDF). Clinical Otolaryngology. 42 (2): 387–396. doi:10.1111/coa.12748. PMID 27608143. S2CID 1060470.
Vos J, de Vey Mestdagh P, Colnot D, Borggreven P, Orelio C, Quak J (December 2017). "Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients". European Archives of Oto-Rhino-Laryngology. 274 (12): 4121–4126. doi:10.1007/s00405-017-4757-7. PMID 28956143. S2CID 20851852.
Bigoni M, Turati M, Zanchi N, Lombardo AS, Graci J, Omeljaniuk RJ, et al. (April 2019). "Clinical applications of Bioactive glass S53P4 in bone infections: a systematic review". European Review for Medical and Pharmacological Sciences. 23 (2 Suppl): 240–251. doi:10.26355/eurrev_201904_17498. PMID 30977891. S2CID 109940029.
Godoy-Santos AL, Rosemberg LA, de Cesar-Netto C, Armstrong DG (January 2019). "The use of bioactive glass S53P4 in the treatment of an infected Charcot foot: a case report". Journal of Wound Care. 28 (Sup1): S14 – S17. doi:10.12968/jowc.2019.28.Sup1.S14. PMID 30724119. S2CID 73428010.
Malat TA, Glombitza M, Dahmen J, Hax PM, Steinhausen E (April 2018). "The Use of Bioactive Glass S53P4 as Bone Graft Substitute in the Treatment of Chronic Osteomyelitis and Infected Non-Unions – a Retrospective Study of 50 Patients". Zeitschrift für Orthopädie und Unfallchirurgie. 156 (2): 152–159. doi:10.1055/s-0043-124377. PMID 29665602. S2CID 263428196.
Lindfors N, Geurts J, Drago L, Arts JJ, Juutilainen V, Hyvönen P, et al. (2017). "Antibacterial Bioactive Glass, S53P4, for Chronic Bone Infections – A Multinational Study". A Modern Approach to Biofilm-Related Orthopaedic Implant Infections. Advances in Experimental Medicine and Biology. Vol. 971. pp. 81–92. doi:10.1007/5584_2016_156. hdl:10138/252437. ISBN 978-3-319-52273-9. PMID 28050878. S2CID 22072415.
Frantzén J, Rantakokko J, Aro HT, Heinänen J, Kajander S, Gullichsen E, et al. (October 2011). "Instrumented spondylodesis in degenerative spondylolisthesis with bioactive glass and autologous bone: a prospective 11-year follow-up". Journal of Spinal Disorders & Techniques. 24 (7): 455–61. doi:10.1097/BSD.0b013e31822a20c6. PMID 21909036. S2CID 28088570.
Rantakokko J, Frantzén JP, Heinänen J, Kajander S, Kotilainen E, Gullichsen E, Lindfors NC (2012). "Posterolateral spondylodesis using bioactive glass S53P4 and autogenous bone in instrumented unstable lumbar spine burst fractures. A prospective 10-year follow-up study". Scandinavian Journal of Surgery. 101 (1): 66–71. doi:10.1177/145749691210100113. PMID 22414472. S2CID 38296163.

sorbonne-universite.fr

hal.sorbonne-universite.fr

Bernardeschi D, Pyatigorskaya N, Russo FY, De Seta D, Corallo G, Ferrary E, et al. (April 2017). "Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass s53p4: a prospective clinical study" (PDF). Clinical Otolaryngology. 42 (2): 387–396. doi:10.1111/coa.12748. PMID 27608143. S2CID 1060470.